ClinicalTrials.gg
CompletedNCT02352493Updated Mar 30, 2020Results posted

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

A Phase 1/2 interventional study of ALN-CC5 and Sterile Normal Saline (0.9% NaCl) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Alnylam Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom — 6 open to participants now, 12 under way, 6 of them phase 3. Hemoglobinuria, Paroxysmal · United Kingdom.

Enrollment
16th of 41
62 · median 29
Started
2015
the only one that year
Phase 1/2
4 of 45
2 open now
Registered
7th of 45
by date
Lead sponsor
1 of 45
Alnylam Pharmaceuticals

Among the 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom, this one is the 16th largest by enrollment of the 41 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1/2, and was the 7th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

6 of the 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hemoglobinuria, Paroxysmal with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • PNH
  • RNAi therapeutic
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate complete blood counts, liver and renal function
  • 12-lead (ECG) within normal limits
  • Female subjects of child bearing potential agreeing to use a protocol specified method of
  • Male subjects agreeing to use protocol specified methods of contraception
  • Willing to provide written and willing to comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk
  • Received an agent within 90 days before the first dose of study drug or are in follow-up of another clinical study
  • History of multiple drug allergies or intolerance to subcutaneous injection
  • Parts A and B of the study: Used prescription medications within 14 days or 7 half-lives of administration of the first dose of study drug.
  • History of meningococcal infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    ALN-CC5

    Drug: ALN-CC5

  • Placebo comparator
    Sterile Normal Saline (0.9% NaCl)

    Drug: Sterile Normal Saline (0.9% NaCl)

Interventions

  • Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection

  • DrugSterile Normal Saline (0.9% NaCl)

    calculated volume to match active comparator

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Adverse events were reported for single-ascending doses (SAD) or multiple ascending doses (MAD) of ALN-CC5 when administered to healthy adult subjects and of multiple doses (MD) in patients with paroxysmal nocturnal hemoglobinuria (PNH)

    Time frame: Part A: through day 658; Part B: through day 532; Part C: through day 280

Secondary outcomes

  1. Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP)

    Complement activity was measured in serum samples collected at timepoints throughout the study using the CAP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CAP from baseline.

    Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140

  2. Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP)

    Complement activity was measured in serum samples collected at time points throughout the study using the CCP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CCP from baseline.

    Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140

  3. Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels

    Total C5 protein levels were measured in serum samples collected at time points throughout the study using a mass spectrometry-based method. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in C5 protein level from baseline.

    Time frame: Part A: through day 70; Part B: through day 140; Part C: through day 140

  4. Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer)

    Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 25-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

  5. Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer)

    Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 23-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

  6. Pharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer)

    Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 25-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

  7. Pharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer)

    Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 23-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

  8. Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer)

    Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 25-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

  9. Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer)

    Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 23-mer.

    Time frame: Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84

07

Results

Posted Mar 30, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Started833333333633333333
Completed833333231533212333
Not completed000000102100121000
Withdrew: Pregnancy000000101000000000
Withdrew: Withdrawal by subject000000001000001000
Withdrew: Lost to follow-up000000000100120000

Outcome measures

PrimaryNumber of Participants With Adverse Events

Adverse events were reported for single-ascending doses (SAD) or multiple ascending doses (MAD) of ALN-CC5 when administered to healthy adult subjects and of multiple doses (MD) in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Time frame:
Part A: through day 658; Part B: through day 532; Part C: through day 280
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
At least 1 Treatment Emergent Adverse Event (TEAE)603223323623332333
At least 1 Serious Adverse Event (SAE)000000000000000000
At least 1 TEAE leading to discontinuation000000000000000000
SecondaryPharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP)

Complement activity was measured in serum samples collected at timepoints throughout the study using the CAP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CAP from baseline.

Time frame:
Part A: through day 70; Part B: through day 140; Part C: through day 140
Reported as:
Mean · percentage reduction
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP)
percentage reductionPlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Alternative Pathway (CAP)18.823 ± 4.302049.321 ± 5.671826.337 ± 5.215964.435 ± 2.313847.628 ± 3.174058.525 ± 5.578272.517 ± 7.544258.914 ± 13.056866.097 ± 7.611325.419 ± 5.915363.224 ± 4.531378.028 ± 5.669270.618 ± 6.783168.367 ± 0.975077.079 ± 1.456476.470 ± 8.156325.951 ± 25.138977.558 ± 5.9434
SecondaryPharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP)

Complement activity was measured in serum samples collected at time points throughout the study using the CCP ELISA assay. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in CCP from baseline.

Time frame:
Part A: through day 70; Part B: through day 140; Part C: through day 140
Reported as:
Mean · percentage reduction
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP)
percentage reductionPlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in Complement Classical Pathway (CCP)18.417 ± 2.768446.953 ± 2.815243.615 ± 6.045872.939 ± 3.483863.582 ± 2.503872.809 ± 1.558987.307 ± 1.375070.830 ± 11.772280.646 ± 4.284925.419 ± 6.275372.340 ± 3.421186.031 ± 4.120988.821 ± 6.322280.126 ± 1.607589.145 ± 1.914775.938 ± 7.278821.333 ± 20.281687.606 ± 4.9981
SecondaryPharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels

Total C5 protein levels were measured in serum samples collected at time points throughout the study using a mass spectrometry-based method. Percentage reduction was calculated relative to baseline levels. A positive value indicates a reduction in C5 protein level from baseline.

Time frame:
Part A: through day 70; Part B: through day 140; Part C: through day 140
Reported as:
Mean · percentage reduction
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels
percentage reductionPlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacodynamic (PD) Effect of ALN-CC5: Percentage Reduction From Baseline in C5 Protein Levels15.88 ± 2.61077.61 ± 3.24973.44 ± 2.88593.17 ± 0.89888.62 ± 0.56594.60 ± 1.37897.62 ± 0.90295.47 ± 0.30697.49 ± 0.25224.302 ± 5.954694.959 ± 0.608798.297 ± 0.490198.428 ± 0.200098.695 ± 0.161298.683 ± 0.316596.870 ± 1.885196.057 ± 1.372898.187 ± 0.2586
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer)

Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 25-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer)
ng/mLALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (25-mer)14.4 ± 2.3313.5 ± 4.3869.8 ± 22.893.9 ± 30.8111 ± 6.56166 ± 42.7217 ± 73.1261 ± 79.521.0 ± 2.6231.5 ± 7.6481.2 ± 16.9283 ± 17.061.7 ± 24.147.3 ± 16.474.1 ± 22.0—
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer)

Maximum observed plasma concentration (Cmax) of ALN-CC5 (cemdisiran) 23-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer)
ng/mLALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: Cmax (23-mer)27.2 ± 4.3530.4 ± 4.21144 ± 39.1178 ± 38.1384 ± 183787 ± 473710 ± 2501500 ± 96632.0 ± 15.444.7 ± 18.1178 ± 17.91080 ± 243167 ± 41.0103 ± 8.48242 ± 78.5—
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer)

Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 25-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Median · hr
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer)
hrALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (25-mer)0.50 (0.50 to 0.50)0.50 (0.50 to 1.00)0.50 (0.50 to 0.50)0.50 (0.50 to 0.50)0.50 (0.50 to 1.00)0.50 (0.50 to 1.00)0.50 (0.50 to 0.50)1.00 (0.50 to 1.00)1.00 (1.00 to 1.00)1.0 (1.00 to 1.00)1.0 (1.00 to 1.00)0.75 (0.50 to 1.00)0.50 (0.50 to 1.00)1.00 (0.50 to 1.00)1.00 (0.5 to 1.50)—
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer)

Time of maximum observed plasma concentration (T max) of ALN-CC5 (cemdisiran) 23-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Median · hr
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer)
hrALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: T Max (23-mer)8.00 (6.00 to 12.00)8.00 (4.00 to 8.00)8.00 (8.00 to 8.02)6.00 (6.00 to 8.00)12.00 (4.00 to 12.02)4.00 (4.00 to 8.00)1.00 (0.50 to 12.00)6.00 (4.00 to 8.00)1.00 (1.00 to 1.00)1.00 (1.00 to 1.00)1.00 (1.00 to 1.00)7.00 (6.00 to 8.00)4.00 (0.50 to 12.00)8.00 (8.00 to 8.00)7.55 (5.93 to 9.17)—
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer)

Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 25-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer)
h*ng/mLALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (25-mer)6.63 ± 3.717.50 ± 4.65182 ± 101198 ± 113287 ± 67.2574 ± 15.6444 ± 78.2757 ± 15410.5 ± 1.3115.8 ± 3.8240.6 ± 8.44843 ± 472110 ± 11.693.5 ± 60.7203 ± 51.0—
SecondaryPharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer)

Area under the plasma concentration-time curve over the dosing interval zero to time (AUC 0-t) of ALN-CC5 (cemdisiran) 23-mer.

Time frame:
Part A: 0-48 hrs, Day 0; Part B (weekly dosing cohorts): 0-48 hrs, Day 28; Part B (biweekly, weekly/monthly/biweekly/monthly cohorts): 0-48 hrs, Day 84; Part C: 0- 24 hrs, Day 84
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer)
h*ng/mLALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
Pharmacokinetic (PK) Effect of ALN-CC5: AUC 0-t (23-mer)258 ± 58.6277 ± 40.92290 ± 3622470 ± 5055450 ± 163010040 ± 32009720 ± 226021540 ± 993016.0 ± 7.7122.3 ± 9.0388.8 ± 8.9514520 ± 22902420 ± 6681700 ± 2192930 ± 13.0—

Adverse events

Collected over Part A: through day 658; Part B: through day 532; Part C: through day 280. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Single Ascending Dose0/8 (0%)0/8 (0%)6/8 (75%)
ALN-CC5 50mg - Single Ascending Dose0/3 (0%)0/3 (0%)0/3 (0%)
ALN-CC5 50mg (Japanese) - Single Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 200mg - Single Ascending Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
ALN-CC5 200mg (Japanese) - Single Ascending Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
ALN-CC5 400mg - Single Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 600mg - Single Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 600mg (Japanese) - Single Ascending Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
ALN-CC5 900mg - Single Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
Placebo - Multiple Ascending Dose0/6 (0%)0/6 (0%)6/6 (100%)
ALN-CC5 100mg Weekly - Multiple Ascending Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
ALN-CC5 200mg Weekly - Multiple Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 400mg Weekly - Multiple Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 600mg Biweekly - Multiple Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 200mg Weekly/Biweekly - Multiple Ascending Dose0/3 (0%)0/3 (0%)2/3 (66.7%)
ALN-CC5 200mg Weekly/Monthly - Multiple Ascending Dose0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 Multiple Dose - Eculizumab Treated0/3 (0%)0/3 (0%)3/3 (100%)
ALN-CC5 Multiple Dose - Eculizumab Naive0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 70
Most frequent other events
EventPlacebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab Naive
NasopharyngitisInfections and infestations3/80/32/31/31/32/31/32/31/34/60/32/31/33/30/32/30/30/3
Injection site painGeneral disorders0/80/30/30/30/30/32/30/30/30/60/30/30/30/30/30/31/30/3
FatigueGeneral disorders0/80/30/30/30/30/30/30/30/30/60/30/30/30/31/30/32/31/3
HeadacheNervous system disorders1/80/31/31/30/30/32/30/32/32/61/32/30/30/30/30/31/31/3
NauseaGastrointestinal disorders2/80/30/30/31/30/32/30/30/31/60/30/30/30/31/30/30/30/3
DiarrhoeaGastrointestinal disorders0/80/30/30/30/30/30/30/30/30/60/31/32/30/30/30/30/30/3
ToothacheGastrointestinal disorders3/80/30/30/30/30/30/30/30/30/60/30/30/30/30/30/30/30/3
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/30/30/30/30/30/30/30/30/61/30/30/30/30/30/30/30/3
Influenza like illnessGeneral disorders0/80/31/30/31/30/31/30/31/30/60/31/30/30/30/30/30/30/3
Injection site rashGeneral disorders0/80/30/30/30/30/31/30/30/30/60/30/31/30/30/30/30/30/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab NaiveTotal
<=18 years0000000000000000000
Between 18 and 65 years83333333363333333362
>=65 years0000000000000000000
Age, Continuous
Age, Continuous(years)Placebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab NaiveTotal
Mean26 ± 5.024 ± 3.233 ± 7.022 ± 1.727 ± 5.023 ± 3.830 ± 6.730 ± 8.027 ± 5.627 ± 6.332 ± 7.629 ± 3.127 ± 2.929 ± 4.226 ± 3.823 ± 6.144 ± 16.944 ± 11.928.6 ± 8.12
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab NaiveTotal
Female20101130241211111224
Male63232203122122222138
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - Single Ascending DoseALN-CC5 50mg - Single Ascending DoseALN-CC5 50mg (Japanese) - Single Ascending DoseALN-CC5 200mg - Single Ascending DoseALN-CC5 200mg (Japanese) - Single Ascending DoseALN-CC5 400mg - Single Ascending DoseALN-CC5 600mg - Single Ascending DoseALN-CC5 600mg (Japanese) - Single Ascending DoseALN-CC5 900mg - Single Ascending DosePlacebo - Multiple Ascending DoseALN-CC5 100mg Weekly - Multiple Ascending DoseALN-CC5 200mg Weekly - Multiple Ascending DoseALN-CC5 400mg Weekly - Multiple Ascending DoseALN-CC5 600mg Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Biweekly - Multiple Ascending DoseALN-CC5 200mg Weekly/Monthly - Multiple Ascending DoseALN-CC5 Multiple Dose - Eculizumab TreatedALN-CC5 Multiple Dose - Eculizumab NaiveTotal
American Indian or Alaska Native0000000000000000000
Asian30303123000000000015
Native Hawaiian or Other Pacific Islander0000000000000000000
Black or African American0102000010000000004
White41010110253333333339
More than one race0000000000000000000
Unknown or Not Reported1100010001000000004
08

Study locations

4 sites
  • Clinical Trial Site
    Barcelona, Spain
  • Clinical Trial Site
    Leeds, United Kingdom
  • Covance Clinical Research Unit
    Leeds, United Kingdom
  • Richmond Pharmacology
    London, United Kingdom
09

References and documents

Publications

  • Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021 Mar;60(3):365-378. doi: 10.1007/s40262-020-00940-9. Erratum In: Clin Pharmacokinet. 2022 Jun;61(6):919. doi: 10.1007/s40262-022-01134-1. PubMed 33047216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Apr 2016 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2015
First posted
Feb 2, 2015
Start
Jan 2015
Primary completionActual
Apr 2016
CompletionActual
Aug 2017
Results first posted
Mar 30, 2020
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02352493
Responsible party
Sponsor
First posted
Feb 2, 2015
Start date
Jan 2015
Primary completion
Apr 2016
Completion
Aug 2017
Results posted
Mar 30, 2020
Last update
Mar 30, 2020

Study contacts

Nader Najafian, MD
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemdisiran

Start the discussion